Aspect Partners’s Centessa Pharmaceuticals CNTA Stock Holding History

Aspect Partners’s Portfolio CNTA Stock Details CNTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-30	Closed	-$1.19K	–	691
2026 Q1	$1.19K	Sell	30 -165	-85%	-$4.22K	﹤0.01%	577
2025 Q4	$4.88K	Sell	195 -35	-15%	-$887	﹤0.01%	383
2025 Q3	$5.58K	Buy	+230	New	+$4.09K	﹤0.01%	399

Aspect Partners's CNTA Position: Q2 2026 in Review

Aspect Partners sold out of Centessa Pharmaceuticals (CNTA) in Q2 2026, closing a stake of 30 shares — an estimated $1.19K sold.

Aspect Partners first reported a position in CNTA in Q3 2025 and held it in 3 quarters. The position peaked at $5.58K in Q3 2025. 0 funds tracked by Wall St. Rank hold CNTA as of Q2 2026.

Aspect Partners reported no remaining Centessa Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Aspect Partners sold 30 Centessa Pharmaceuticals shares in Q2 2026, an estimated $1.19K.
Aspect Partners first reported a position in Centessa Pharmaceuticals in Q3 2025 and held it in 3 quarters.
Aspect Partners's Centessa Pharmaceuticals position peaked at $5.58K in Q3 2025.
0 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q2 2026.

Based on Aspect Partners's 13F filing for Q2 2026, filed 16 Jul 2026.